Current Edition


How to Bring Your Oncolytic Virus Innovation to Market: the Secret to Successful Development

Cancer continues to be a major burden on healthcare systems across the world, with global spending on therapies and supportive care drugs expected to reach …

Continue Reading →

Vyriad signs a contract with IBM to build an oncolytic virus anti-cancer vaccines manufacturing facility

The custom buildout will be financed with proceeds from a recently completed $9 million secured convertible note financing, which included participation by Mayo Clinic, Rochester …

Continue Reading →